Others have shown a correlation between TMPRSS2-ERG gene fusion, grade [194,195] and stage [196] at diagnosis, with analysis of the gene fusion also demonstrated to have the ability to predict the risk of clinically relevant PC after a prostatic biopsy [189]. This evidence concerns the gene ERG and pachyonychia congenita.